Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study

Authors

Xian‐Long Meng
Guo‐Huan Yang (ORCID: https://orcid.org/0009-0008-3287-4454)
Hui‐Chuan Sun (ORCID: https://orcid.org/0000-0003-3761-7058)
Fei Liang (ORCID: https://orcid.org/0000-0002-4184-7844)
Jia‐Cheng Lu
Xiaojun Guo (ORCID: https://orcid.org/0000-0003-0139-3486)
Yi Chen (ORCID: https://orcid.org/0000-0002-1970-9322)
Yuan Ji (ORCID: https://orcid.org/0009-0002-3383-8072)
Cheng Zhang (ORCID: https://orcid.org/0000-0002-9722-243X)
Zhitao Zheng
Jia Fan
Zhiqiang Hu (ORCID: https://orcid.org/0000-0002-0802-8580)
Xiaoyong Huang (ORCID: https://orcid.org/0000-0002-5946-4737)
Jian Zhou (ORCID: https://orcid.org/0000-0002-9917-5622)
Guo‐Ming Shi (ORCID: https://orcid.org/0000-0003-3446-7875)

Institutions

Sun Yat-sen University (CN)
Fudan University (CN)
Zhongshan Hospital (CN)
The First Affiliated Hospital, Sun Yat-sen University (CN)

Publication Details

Journal: BMC Medicine
Published: 2025-10-21
DOI: https://doi.org/10.1186/s12916-025-04404-4
Citations: 3
Primary Topic: Cholangiocarcinoma and Gallbladder Cancer Studies
Type: article
Field-Weighted Citation Impact: 6.02

Funders

Natural Science Foundation of Shanghai
National Natural Science Foundation of China
Fudan University
Sanming Project of Medicine in Shenzhen
National Key Research and Development Program of China
Program of Shanghai Academic Research Leader

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study

Xian‐Long Meng, Guo‐Huan Yang, Hui‐Chuan Sun, Fei Liang et al.

Oct 21, 2025

3 citations

BMC Medicine

Cholangiocarcinoma and Gallbladder Cancer Studies

6.02

article

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study

Xian‐Long Meng, Guo‐Huan Yang, Hui‐Chuan Sun, Fei Liang, Jia‐Cheng Lu, Xiaojun Guo, Yi Chen, Yuan Ji, Cheng Zhang, Zhitao Zheng, Jia Fan, Zhiqiang Hu, Xiaoyong Huang, Jian Zhou, Guo‐Ming Shi

October 21, 2025article en

3 citations

Abstract

No abstract available for this paper.

BMC MedicineVol. 23(1)

Sun Yat-sen University (CN), Fudan University (CN), Zhongshan Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN)

Natural Science Foundation of Shanghai, National Natural Science Foundation of China, Fudan University, Sanming Project of Medicine in Shenzhen, National Key Research and Development Program of China, Program of Shanghai Academic Research Leader

Openalex Percentile: Top 3%

Cholangiocarcinoma and Gallbladder Cancer Studies

6.02

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.